A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

NCT00943553 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Terminated by Sponsor

Conditions

Acute Myelogenous Leukemia (AML)

Interventions

DRUG: decitabine Induction Chemotherapy
DRUG: Induction Chemotherapy

Sponsor

Eisai Inc.